-
ICD-10-CM Codes
›
-
C00-D49
Neoplasms
›
-
C7B-C7B
Secondary neuroendocrine tumors
›
-
C7B-
Secondary neuroendocrine tumors
›
-
2021 ICD-10-CM Diagnosis Code C7B
2021 ICD-10-CM Diagnosis Code C7B
Secondary neuroendocrine tumors
2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
- C7B should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2021 edition of ICD-10-CM C7B became effective on October 1, 2020.
- This is the American ICD-10-CM version of C7B - other international versions of ICD-10 C7B may differ.
Use AdditionalUse Additional Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
- code to identify any functional activity
The following code(s) above
C7B contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
C7B:
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
Code annotations containing back-references to C7B:
ICD-10-CM Codes Adjacent To C7B
C7A.090 Malignant carcinoid tumor of the bronchus and lung
C7A.091 Malignant carcinoid tumor of the thymus
C7A.092 Malignant carcinoid tumor of the stomach
C7A.093 Malignant carcinoid tumor of the kidney
C7A.094 Malignant carcinoid tumor of the foregut, unspecified
C7A.095 Malignant carcinoid tumor of the midgut, unspecified
C7A.096 Malignant carcinoid tumor of the hindgut, unspecified
C7A.098 Malignant carcinoid tumors of other sites
C7A.1 Malignant poorly differentiated neuroendocrine tumors
C7A.8 Other malignant neuroendocrine tumors
C7B
Secondary neuroendocrine tumors
C7B.0 Secondary carcinoid tumors
C7B.01 …… of distant lymph nodes
C7B.1 Secondary Merkel cell carcinoma
C7B.8 Other secondary neuroendocrine tumors
C76 Malignant neoplasm of other and ill-defined sites
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.